Evaluation of rosiglitazone administration on cardiovascular function in severe obesity

Clinical Cardiology

Volumn 31, Issue 12, 2008, Pages 602-606

  Brunani, Amelia ^a,c   Liuzzi, Antonio ^a   Titon, AnnaMaria ^a   Graci, Salvatore ^a   Castagna, Giovanna ^a   Viberti, Gian Carlo ^b   Gondoni, Luca A ^a  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Ospedale San Giuseppe   (Italy)

Author keywords

Left ventricular function; Obesity; Rosiglitazone; Tissue doppler imaging

Indexed keywords

ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BASAL METABOLIC RATE; BLOOD PRESSURE MONITORING; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; DISEASE SEVERITY; DOPPLER ECHOGRAPHY; DRUG EFFECT; FEMALE; GLUCOSE METABOLISM; HEART LEFT VENTRICLE FUNCTION; HEART PRELOAD; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LOW CALORY DIET; MALE; MORPHOMETRICS; OBESITY; SYSTOLIC BLOOD PRESSURE; TISSUE DOPPLER IMAGING; TWO DIMENSIONAL ECHOCARDIOGRAPHY; WATER CONTENT; WEIGHT CHANGE;

ADULT; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR SYSTEM; DIASTOLE; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; OBESITY; PPAR GAMMA; SYSTOLE; THIAZOLIDINEDIONES; VENTRICULAR FUNCTION, LEFT;

EID: 58149098313     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.20339     Document Type: Article

References (21)

1. Hirayama H, Sugano M, Abe N, Yonemoch H, Makino N: Troglitazone, an antidiabetic drug, improves left ventricular mass and diastolic function in normotensive diabetic patients. Int J Cardiol 2001;77:75-79
2. Martens FM, Visseren FL, Lemay J, de Konong EJ, Rabelink TJ: Metabolic and additional vascular effects of thiazolinediones. Drugs 2002;62:1463-1480
3. Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:1-15
4. Hollenberg NK: Considerations for management of fluid dynamic issues associated with thiazolinediones. Am J Med 2003;115(Suppl 8A):111S-115S
5. Peterson RL, Waggoner AD, Schetchman KB, Meyer T, Gropler RJ, et al.: Alterations in left ventricular structure and function in young healthy obese women. J Am Coll Cardiol 2004;43:1399-1404
6. Piccoli A, Brunani A, Savia G, Pillon L, Favaro E et al.: Discriminating between body fat and fluid overload changes in the obese adults using bioimpedance vector analysis. Int J Obes 1998;22:97-104
7. Matthews DR, Hosker JP, Rudenski AS, Naylor BA Teacher DF, et al.: Homeostasismodel assessment, insulin resistance and β cell function from fasting plasma glucose and insulin concentration in human. Diabetologia 1985;28:412-419
8. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613-618
9. Sutton MSJ, Rendell M, Dandona P, Dole JF, Murphy K, et al.: Rosiglitazone clinical trias study froup. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058-2064
10. Kiryluk K, Isom R: Thiazolidinediones and fluid retention. Kidney Int 2007;72:762-768
11. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, et al.: Thiazolidinediones use, fluid retention and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-1948
12. Kim SH, Abbassi F, Chu JW, McLaughlin TL, Lamendola C, et al.: Rosiglitazone reduces glucose-stimulated insulin secretion rate and increases insulin clearance in nondiabetic, insulin-resistant individuals. Diabetes 2005;54:2447-2452
13. Avandia (rosiglitazone maleate) tablets: prescribing information. Research Triangle Park, NC: GlaxoSmithKline; 2007 (package insert)
14. Sotiropoulos KB, Clermont A, Yasuda Y, Rask-Madsen C, Mastumoto M et al. Adipose-specific effect of rosiglitazone on vascular permeability and protein kinase C activation: novel mechanism for PPARgamma agonist's effects on edema and weight gain. FASEB J 2006;20:1203-1205
15. Pickavence LC, Tadayyon M, Widdowson PS, Buckingham RE, Wilding JPH: Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. Br J Pharmacol 1999;128:1570-1576
16. Rennings AJM, Smits P, Stewart MW, Tack CJ. Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects. Diabetes Care 2006;29:581-587
17. Sarafidis PA, Nilsson PM: The effects of thiazolidinediones on blood pressure levels - a systemic review. Blood Press 2006;15:135-150
18. Amà R, Segers P, Roosens C, Claessens T, Verdonck P, et al.: The effects of load on systolic mitral annular velocity by tissue Doppler imaging. Anesth Analg 2004;99:332-338
19. Gondoni LA, Titon AM, Silvestri G, Nibbio F, Taronna O, et al.: Short term effects of physical exercise and low calorie diet on left ventricular function in obese subjects: a tissue Doppler study. Nutr Metab Cardiovasc Dis 2007;17:358-364
20. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Matthew WR, et al.: Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005;146:5341-5349
21. Kelly AS, Bank AJ: The cardiovascular effects of the thiazolidinediones: a review of the clinical data. J Diabetes Complications 2007;21:326-334